REVESTIVE teduglutide 5 mg powder for solution for injection vial with diluent pre-filled syringe Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

revestive teduglutide 5 mg powder for solution for injection vial with diluent pre-filled syringe

takeda pharmaceuticals australia pty ltd - water for injections, quantity: 0.5 ml - injection, solution - excipient ingredients: - revestive is indicated for the treatment of adult and paediatric patients 2 years of age and above with short bowel syndrome (sbs) who are dependent on parenteral support.,patients should be stable for at least 4 weeks on their parenteral support regimen before initiating teduglutide therapy

PERGOVERIS follitropin alfa (rch) /lutropin alfa (rch) 900 IU/450 IU in 1.44 mL solution for injection cartridge pre-assembled in a pen Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

pergoveris follitropin alfa (rch) /lutropin alfa (rch) 900 iu/450 iu in 1.44 ml solution for injection cartridge pre-assembled in a pen

merck healthcare pty ltd - follitropin alfa, quantity: 625 iu/ml; lutropin alfa, quantity: 312.5 iu/ml - injection, solution - excipient ingredients: sucrose; poloxamer; methionine; phenol; arginine hydrochloride; dibasic sodium phosphate dihydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; phosphoric acid; water for injections - pergoveris is indicated for the stimulation of follicular development in women with severe lh and fsh deficiency.

PERGOVERIS follitropin alfa (rch) /lutropin alfa (rch) 450 IU/225 IU in 0.72 mL solution for injection cartridge pre-assembled in a pen Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

pergoveris follitropin alfa (rch) /lutropin alfa (rch) 450 iu/225 iu in 0.72 ml solution for injection cartridge pre-assembled in a pen

merck healthcare pty ltd - follitropin alfa, quantity: 625 iu/ml; lutropin alfa, quantity: 312.5 iu/ml - injection, solution - excipient ingredients: sucrose; poloxamer; methionine; phenol; arginine hydrochloride; dibasic sodium phosphate dihydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; phosphoric acid; water for injections - pergoveris is indicated for the stimulation of follicular development in women with severe lh and fsh deficiency.

PERGOVERIS follitropin alfa (rch) /lutropin alfa (rch) 300 IU/150 IU in 0.48 mL solution for injection cartridge pre-assembled in a pen Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

pergoveris follitropin alfa (rch) /lutropin alfa (rch) 300 iu/150 iu in 0.48 ml solution for injection cartridge pre-assembled in a pen

merck healthcare pty ltd - follitropin alfa, quantity: 625 iu/ml; lutropin alfa, quantity: 312.5 iu/ml - injection, solution - excipient ingredients: sucrose; poloxamer; methionine; phenol; arginine hydrochloride; dibasic sodium phosphate dihydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; phosphoric acid; water for injections - pergoveris is indicated for the stimulation of follicular development in women with severe lh and fsh deficiency.

Revestive Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

revestive

takeda new zealand limited - teduglutide 5mg; water for injection 0.5 ml - powder for injection with diluent - 5 mg - active: teduglutide 5mg excipient: dibasic sodium phosphate heptahydrate histidine hydrochloric acid mannitol monobasic sodium phosphate monohydrate sodium hydroxide water for injection active: water for injection 0.5 ml - revestive is indicated for the treatment of adult patients with short bowel syndrome (sbs) who are dependent on parenteral support. patients should be stable at least to 4 weeks on their parenteral support regimen before initiating teduglutide therapy

PERGOVERIS follitropin alfa (rch) / lutropin alfa (rch) powder for injection vial with diluent vial Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

pergoveris follitropin alfa (rch) / lutropin alfa (rch) powder for injection vial with diluent vial

merck healthcare pty ltd - follitropin alfa, quantity: 150 iu; lutropin alfa, quantity: 75 iu - injection, powder for - excipient ingredients: sucrose; dibasic sodium phosphate dihydrate; monobasic sodium phosphate monohydrate; methionine; polysorbate 20; phosphoric acid; sodium hydroxide - pergoveris is indicated for the stimulation of follicular development in women with severe lh and fsh deficiency.

PERGOVERIS SOLUTION FOR INJECTION IN PRE-FILLED PEN (300 IU + 150 IU)0.48 mL Сингапур - Енглески - HSA (Health Sciences Authority)

pergoveris solution for injection in pre-filled pen (300 iu + 150 iu)0.48 ml

merck pte. ltd. - follitropin alfa (r-hfsh); lutropin alfa (r-lh) - injection, solution - follitropin alfa (r-hfsh) 300 iu/0.48ml; lutropin alfa (r-lh) 150 iu/0.48ml

PERGOVERIS SOLUTION FOR INJECTION IN PRE-FILLED PEN (450 IU + 225 IU)0.72 mL Сингапур - Енглески - HSA (Health Sciences Authority)

pergoveris solution for injection in pre-filled pen (450 iu + 225 iu)0.72 ml

merck pte. ltd. - follitropin alfa (r-hfsh); lutropin alfa (r-lh) - injection, solution - follitropin alfa (r-hfsh) 450 iu/0.72ml; lutropin alfa (r-lh) 225 iu/0.72ml

PERGOVERIS SOLUTION FOR INJECTION IN PRE-FILLED PEN (900 IU + 450 IU)1.44 mL Сингапур - Енглески - HSA (Health Sciences Authority)

pergoveris solution for injection in pre-filled pen (900 iu + 450 iu)1.44 ml

merck pte. ltd. - follitropin alfa (r-hfsh); lutropin alfa (r-lh) - injection, solution - follitropin alfa (r-hfsh) 900iu/1.44ml; lutropin alfa (r-lh) 450 iu/1.44ml

LUVERIS lutropin alfa (rch) 75IU powder for injection vial with diluent vial Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

luveris lutropin alfa (rch) 75iu powder for injection vial with diluent vial

merck healthcare pty ltd - lutropin alfa, quantity: 75 iu - injection, powder for - excipient ingredients: methionine; sodium hydroxide; phosphoric acid; sucrose; polysorbate 20; dibasic sodium phosphate dihydrate; monobasic sodium phosphate monohydrate - luveris in association with a recombinant follicle stimulating hormone (fsh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials, these patients were defined by an endogenous serum lh of less than 1.2 iu/l.